GSK Acquires Nuvalent to Expand Oncology Pipeline | Lucid Diligence Brief
GSK strengthens its oncology portfolio with Nuvalent acquisition, adding…
GNI Group Acquires Ayumi Pharmaceutical | Lucid Diligence Brief
GNI Group’s Ayumi acquisition tests Japan commercial scale, Calonal durability,…
Ascidian and Lilly $1.9B Deal for Kidney RNA Editing | Lucid Diligence Brief
Ascidian and Lilly $1.9B collaboration tests whether RNA exon editing can move…
Haisco Lilly Collaboration | Lucid Diligence Brief
Haisco’s Lilly Deal Tests China-Originated Small-Molecule Discovery…
Pfizer Innovent Oncology Deal | Lucid Diligence Brief
Pfizer Innovent Oncology Deal tests China-originated ADC and multi-specific…
Lucid Diligence Brief: Cullinan Therapeutics Gains FDA Orphan Drug Designation for CLN-049
Lucid Diligence Brief: Cullinan Therapeutics Receives FDA Orphan Drug…
Lucid Diligence Brief: Helio Genomics and Syneos Health Deal
Lucid Diligence Brief: Helio Genomics and Syneos Health Deal to expand…
Lucid Diligence Brief: Iterative Health Acquisition of NextStage Cardiology Research Sites
Lucid Diligence Brief: Iterative Health Acquisition of NextStage Cardiology…
Lucid Diligence Brief: ERS Genomics and Aurigene CRISPR/Cas9 License
Lucid Diligence Brief: ERS Genomics’ CRISPR/Cas9 IP license to Aurigene raises…
Lucid Diligence Brief: Basata $21 million Series A
Lucid Diligence Brief: Basata $21 million Series A Professional audiences only.…
Lucid Diligence Brief: Arrowhead ARO-PNPLA3 licensed to Madrigal
Lucid Diligence Brief: Arrowhead ARO-PNPLA3 licensed to Madrigal Professional…
Lucid Diligence Brief: Latus Bio $97 million Series A
Lucid Diligence Brief: Latus Bio $97 million Series A Professional audiences…